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Abstract
Background: Prostaglandin (PG) production is associated with inflammation, a major feature in
multiple sclerosis (MS) that is characterized by the loss of myelinating oligodendrocytes in the CNS.
While PGs have been shown to have relevance in MS, it has not been determined whether PGs
have a direct effect on cells within the oligodendrocyte lineage.
Methods: Undifferentiated or differentiated mouse oligodendrocyte precursor (mOP) cells were
treated with PGE2, PGF2α, PGD2 or 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2). Cell growth and survival
following treatment were examined using cytotoxicity assays and apoptosis criteria. The membrane
receptors for PGD2 and the nuclear receptor peroxisome proliferator-activated receptor
(PPAR)γ, as well as reactive oxygen species (ROS) in the death mechanism were examined.
Results: PGE2 and PGF2α had minimal effects on the growth and survival of mOP cells. In
contrast, PGD2 and 15d-PGJ2 induced apoptosis of undifferentiated mOP cells at relatively low
micromolar concentrations. 15d-PGJ2 was less toxic to differentiated mOP cells. Apoptosis was
independent of membrane receptors for PGD2 and the nuclear receptor PPARγ. The cytotoxicity
of 15d-PGJ2 was associated with the production of ROS and was inversely related to intracellular
glutathione (GSH) levels. However, the cytotoxicity of 15d-PGJ2 was not decreased by the free
radical scavengers ascorbic acid or α-tocopherol.
Conclusion: Taken together, these results demonstrated that 15d-PGJ2 is toxic to early stage OP
cells, suggesting that 15d-PGJ2 may represent a deleterious factor in the natural remyelination
process in MS.
Background
Prostaglandin (PG)s are a group of 20-carbon fatty acids
derived from membrane lipids. By sequential enzymatic
reactions of phospholipase A2 (PLA2), housekeeping
cyclooxygenase (COX)-1 or inducible COX-2, PGH2 is
generated and then converted to PGE2, PGD2, PGF2α,
PGI2 (prostacyclin) and TXA2 (thromboxane A2) by their
respective PG isomerases [1]. For example, PGH2 is first
converted to PGD2 by lipocalin-type PGD2 synthase (L-
PGDS) or hematopoietic (H)-PGDS, which then under-
goes sequential non-enzymatic dehydration reactions to
form 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2). PGs generally act
through membrane-bound G-protein coupled PG recep-
tors with the exception of 15d-PGJ2, which has no
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defined membrane receptor, although reported to be an
activator of the PGD2 receptor DP2 [2]. Instead, 15d-PGJ2
is a natural ligand for the nuclear receptor peroxisome
proliferator-activated receptor (PPAR)γ [3], which has a
major role in the regulation of proliferation, differentia-
tion and lipid metabolism [4,5]. Moreover, 15d-PGJ2 has
been shown to induce apoptosis of cultured cortical neu-
rons [6,7], endothelial cells [8], hepatic myofibroblasts
[9], granulocytes [10] and cancer cells [11], through both
PPARγ-dependent and PPARγ-independent mechanisms
[9,10].
Mounting evidence suggests that PGs play important roles
in neuroinflammatory diseases such as multiple sclerosis
(MS), an autoimmune disease of the central nervous sys-
tem (CNS) in which T- and B cells attack components of
the myelin sheath leading to loss of myelin as well as mye-
linating oligodendrocytes [12-14]. As a natural repair
mechanism, oligodendrocyte precursor (OP) cells prolif-
erate and differentiate within the demyelination sites to
replenish the lost myelinating oligodendrocytes [15,16].
In patients with MS and in the experimental autoimmune
encephalomyelitis (EAE) rodent model, the demyelina-
tion foci are typically characterized by inflammatory infil-
trates containing myelin-specific T- and B cells, and
activated microglia and astrocytes [12,14,17-19]. These
inflammatory cells are known to secrete cytotoxic
cytokines such as TNFα and interleukin (IL)-6 [12,20], as
well as PGs such as PGE2, PGD2 and PGF2α [21-23]. Bac-
terial lipopolysaccharide (LPS), which is a potent proin-
flammatory factor that induces abundant PGD2 or 15d-
PGJ2 production in microglia cultures [24,25], and in the
CSF and spinal cord following systemic administration
[26,27]. In MS demyelination foci, gene expression of PG
related enzymes such as PLA2 [28], COX-2 [29] and L-
PGDS [30] are up-regulated. Increased L-PGDS in peri-
neuronal oligodendrocytes and H-PGDS in microglia are
also observed in the mouse twitcher demyelination model
[31,32]. Additional evidence has shown that H-PGDS is
increased in activated T helper (Th)2 cells in vitro [23].
While these findings suggest that OP cells are exposed to
a PG-rich environment, little is known regarding the effect
these PGs have on OP cells.
In this study, we examined the effect of PGs on mouse OP
(mOP) cells. We found that PGD2 and its dehydration
end product 15d-PGJ2 induce apoptosis of OP cells in a
PPARγ-independent manner, while more mature OP cells
are relatively resistant. These results suggest that PGD2
and 15d-PGJ2 may contribute to MS pathology by induc-
ing OP cell death.
Methods
Materials and reagents
N1 supplement, insulin, biotin, staurosporine, indometh-
acin, NS398, SC58125, GW9662, N-acetyl cysteine
(NAC), buthionine sulfoximine (BSO), ascorbic acid, α-
tocopherol, poly-D-lysine, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) and bisbenzim-
ide were obtained from Sigma (St. Louis, MO); High glu-
cose DMEM, DMEM/F12 (1:1), fetal bovine serum,
penicillin/streptomycin, Trizol, PCR reagents and
enzymes were from Invitrogen (Carlsbad, CA); SYBR
green PCR mix was from Amersham (Piscataway, NJ);
15d-PGJ2, PGD2, PGE2, PGF2α, T0070907, AH6809,
BAY-u3405 and GSH kit were from Cayman Chemicals
(Ann Arbor, MI); Cover-slips were from Bellco Biotech-
nology (Vineland, NJ); LDH cytotoxicity assay kit was
from Promega (Madison, WI); TUNEL kit and cell death
ELISA kit were from Roche (Indianapolis, IN); Fluores-
cence probe 5-(and-6)-carboxy-2',7'-dichlorodihydroflu-
orescein diacetate (carboxy-H2DCFDA) was from
Molecular Probes (Eugene, OR); Goat anti-MBP was from
Santa Cruz Biotechnology (Santa Cruz, CA); rabbit anti-
NG2 was kindly provided by Dr. W. Stallcup; rabbit anti-
πGST was from MBL (Woburn, MA); A2B5 hybridoma
was from ATCC (Menassas, VA); normal donkey serum
and all secondary antibodies were from Jackson Immu-
noResearch (West Grove, PA); Fluorescent mounting
medium with or without nuclear dye DAPI was from Vec-
tor Laboratories (Burlingame, CA).
Mouse oligodendrocyte precursor (mOP) cell line
The mOP cell line developed in this lab [33] and the rat
oligodendrocyte cell line CG4 [34] were used in this
study. Both cell lines were maintained in CG4 prolifera-
tion medium (PM) as described previously [34]. CG4 PM
consists of 70% high glucose DMEM, 30% conditioned
medium from B104 neuroblastoma cell line, supple-
mented with 0.5% N1 supplements, biotin 10 μg/ml,
insulin 5 μg/ml and 1% penicillin/streptomycin.
Differentiation of mOP cells was induced in differentia-
tion medium (DM), which is different from CG4 PM only
in that the 30% conditioned medium was from confluent
mOP cell cultures instead of B104 neuroblastoma cul-
tures. The use of conditioned medium from confluent
mOP cells was based on the previous report that oli-
godendrocytes are self-inhibiting in proliferation [34] and
our observation of a differentiation-promoting effect
from medium obtained from confluent mOP cell cultures
(data not shown). Conditioned medium from confluent
cells was obtained as follows: Approximately 50% conflu-
ent mOP cell cultures were grown for 1 wk in PM without
medium change, medium was collected, filtered, and then
used to make DM. mOP cells were cultured in DM for 3 d
before treatments.Journal of Neuroinflammation 2007, 4:18 http://www.jneuroinflammation.com/content/4/1/18
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Drug treatment of cell cultures
mOP cell cultures were grown to 60–70% confluency in
12- or 24-well plates and then serum-starved (CG4 PM
without conditioned medium) for 24 h before experi-
ments. PGs were added to the medium for 24–48 h. For
15d-PGJ2 or PGD2 preparation, the original solvent ethyl
acetate was evaporated, and PGD2 or 15d-PGJ2 was re-
dissolved in PBS before adding to the medium. For other
chemicals, a corresponding amount of the solvent
(DMSO or ethanol) was added to control cultures with
concentrations less than 0.2%. All experiments were per-
formed 3–5 times and each treatment in triplicates.
Cell growth/viability assay
Cells were assayed using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT). MTT is con-
verted to a blue formazan product by mitochondria dehy-
drogenases only in live cells, and can be used as a
cytotoxicity assay [35]. In this regard, the MTT assay has
been used to specifically address 15d-PGJ2-induced cell
death in neurons and endothelial cells [7,8]. Cells were
incubated in medium with MTT (50 μg/ml) for 1 h at
37°C. The formazan product was dissolved in DMSO, and
absorbance at 600 nm was measured using a plate reader.
Additionally, lactate dehydrogenase (LDH) enzymatic
activity in the medium was measured using the
CytoTox96 kit (Promega) according to the manufacturer's
instructions. LDH is released into the medium upon cell
lysis, and the activity measured in the medium is therefore
proportional to the number of lysed cells. The amount of
cell death (percentage) was calculated as released LDH/
total LDH (value obtained by lysing all cells in the
untreated wells).
Terminal deoxynucleotidyl transferase (TdT) dUTP nick 
end labeling (TUNEL) and nuclear staining
TUNEL staining was performed using a kit from Roche fol-
lowing the manufacturer's instructions. In brief, cells that
had been grown on coverslips were fixed in 4% parafor-
maldehyde for 20 min and then rinsed in PBS. After per-
meablization for 15 min at RT with 0.1% Triton X-I00 in
0.1% citrate buffer, the cells were incubated with TUNEL
mix (TdT enzyme and fluorescein-dUTP) for 1 h at 37°C.
After rinsing with PBS, the coverslips were mounted on
glass slides with fluorescence mounting medium and
inspected under a fluorescence microscope. Four random
areas for each coverslip (20× objective view) were sur-
veyed and the number of cells counted. For nuclear stain-
ing, bisbenzimide was added to the medium at 1 μg/ml
for 20 min. After washing, mOP cells were mounted for
fluorescence microscopy.
ELISA-based cell death assay
Apoptotic cell death was also quantified using an ELISA
kit that quantifies indirectly the histone-containing nucle-
osomes after DNA fragmentation. The culture medium
was collected. Attached cells were then collected using
trypsin digestion (0.25% for 5 min), combined with the
culture supernatant, and then the mix was pelleted at
1,500 × g for 5 min. After carefully removing the superna-
tant, the cells were lysed in incubation buffer for 30 min
at RT. After centrifugation at 20,000 × g for 10 min, the
supernatants (cytoplasmic fraction containing nucleo-
somes) were added to the plate according to the manufac-
turer's instructions. DNA fragmentation was then
examined calorimetrically using a plate reader at 405 nm.
DNA gel electrophoresis
Cells were harvested and lysed in hypotonic buffer (50
mM Tris (pH7.9) containing 1% Triton X-I00, 10 mM
EDTA and 50 μg/ml RNase A) for 5 min at RT. The lysates
were centrifuged at 10,000 × g for 10 min, and the super-
natant containing short DNA fragments was collected.
After phenol/chloroform extraction, DNA was precipi-
tated with sodium acetate and ethanol, resuspended in TE
buffer, separated on a 1.2% agarose gel containing ethid-
ium bromide and then visualized with a UV illuminator.
Immunocytochemistry
mOP cells grown on poly-D-lysine coated cover-slips were
fixed in 4% paraformaldehyde for 20 min and rinsed in
PBS. After permeablization for 15 min at RT with 0.2%
Triton X-I00 in PBS and 10% normal donkey serum to
block unspecific binding, mOP cells were incubated with
primary antibodies: goat anti-MBP (1: 100), rabbit anti-
NG2 (1: 200), rabbit anti-GST (1: 1000), all diluted in
PBS with 1% normal donkey serum. For A2B5, hybrid-
oma medium was used directly without dilution. After
three washes with PBS, the cells were incubated with
appropriate Cy2- or Cy3-conjugated secondary antibodies
(1:200 in PBS with 1% donkey serum) for 1 h at RT in the
dark. After PBS washes, the cover-slips were mounted on
slides with fluorescence mounting medium containing
the nuclear dye DAPI and examined using an Olympus
BX60 microscope equipped with epifluorescence optics.
Reactive oxygen species (ROS) detection
ROS production was detected using the fluorescence
probe carboxy-H2DCFDA. mOP cells plated on poly-D-
lysine coated coverslips were washed twice with DMEM
and then incubated in loading solution (DMEM with 25
μM DCFDA) for 30 min at 37°C in the dark. Cells were
washed twice and then treated with 15d-PGJ2. Coverslips
were rinsed with DMEM before mounting on slides and
fluorescence (FITC filter) images of cells were taken
immediately using a fluorescence microscope equipped
with a digital camera (DP70, Sony). Ten fields (40× objec-
tive) for each coverslip were sampled (>400 cells), the
mean pixel values (0–255) of individual cells were ana-
lyzed using NIH imaging software (NIH, Bethesda, MD).Journal of Neuroinflammation 2007, 4:18 http://www.jneuroinflammation.com/content/4/1/18
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All treatments were performed in duplicate and data
expressed were averaged values of all cells counted in each
condition.
GSH measurement
Total intracellular GSH content was measured using a kit
from Cayman according to the manufacturer's instruc-
tions. In brief, mOP cells were scraped from 6-well plate,
pelleted by centrifugation at 700 × g for 5 min, homoge-
nized in 1 ml cold buffer, and then centrifuged at 10,000
× g for 15 min at 4°C. The supernatant was collected and
protein concentration was measured. The supernatant was
deproteinated by mixing with metaphosphoric acid
before GSH content measurement. GSH content was
expressed as μmol/mg protein.
RT-PCR
Total RNA was isolated using the Trizol reagent according
to the manufacturer's instructions. First-strand cDNA was
synthesized using reverse transcriptase (Superscript) and
oligo(dT) primer. PCR reactions were performed using 1
μg cDNA and Taq polymerase. Primers for PPARγ amplifi-
cation were: 5'-TTT TCA AGG GTG CCA GTT TC-3' and 5'-
AAT CCT TGG CCC TCT GAG AT-3'. The expected PCR
product size is 198 bp. All reactions were carried out with
iCycler (BioRad, Hercules, CA) using SYBR green PCR
mix, which allows automated signal quantification. The
PCR parameters were 35 cycles with 94°C denaturation
for 20 sec, 60°C annealing for 30 sec, and 72°C extension
for 50 sec. Quantification was performed using the ΔΔ
method. The PCR products were confirmed by ethidium
bromide-stained agarose gel electrophoresis. cDNA
derived from a postnatal day 20 mouse brain was used as
a positive control.
Statistics
Statistical analysis was performed using InStat and Prism
software (GraphPad Software, San Diego, CA). Student t-
test (two-tailed) was used to assess the difference between
two groups. One-way ANOVA was used to assess differ-
ences among groups (more than three) with Newman-
Keuls post-test. When appropriate, two-way ANOVA and
Bonferroni posttest were used to assess differences among
groups with two independent variables. All significance
levels were set at p < 0.05.
Results
PGD2 and 15d-PGJ2 but not PGE2 or PGF2α induced mOP 
cell death
We have previously developed mouse OP (mOP) cells
[33] from the post-natal mouse brain that can be sus-
tained for long periods in culture and which display prop-
erties similar to those of the rat CG4 oligodendrocyte cell
line [34]. When grown in proliferation medium (PM)
mOP cells assume bipolar or tripolar morphology and
express the OP cell markers NG2 and A2B5 (Fig. 1A). We
first examined whether endogenous PG production by oli-
godendrocytes has a role in mOP cell growth and survival.
In these experiments we used MTT assay as an initial assay
for cell death and chemical inhibitors of enzymes respon-
sible for PG production. mOP cells were treated with 10
μM of indomethacin (COX-1 and COX-2 inhibitors),
NS398 (COX-2 specific inhibitor) or SC58125 (COX-2
specific inhibitor) for 48 h. No differences in mOP cell
growth and survival were observed compared to vehicle
treated (Data not shown). We next tested whether direct
applications of PGs to the culture medium of mOP cells
affected growth and survival. PGE2 or PGF2α treatment
(0.1, 1 and 10 μM) for 24 h had no effect on mOP cell
growth (Fig. 1B). Extended treatment with PGE2 or
PGF2α (10 μM) for 48 h also had no effect (data not
shown). In contrast, PGD2 and 15d-PGJ2 induced signif-
icant cell death in a dose-dependent manner as early as 24
h (Fig. 1C–D). mOP cells were more sensitive to 15d-PGJ2
(50% effective concentration (EC50) 1.0 μM) than to
PGD2 (EC50 16.6 μM). To confirm the cytotoxicity of
15d-PGJ2, we used a more specific cell death assay, which
measures the enzymatic activity of lactate dehydrogenase
(LDH) released in the medium by dead cells. Treatment of
15d-PGJ2 (1.0 μM) induced significant cell death at 24 h,
and more dramatically at 48 h. The effect of these PGs was
also examined on the rat oligodendrocyte cell line CG4
using MTT assay and similar results were observed (data
not shown).
Apoptotic death of mOP cells induced by 15d-PGJ2
We next examined whether mOP cell death induced by
15d-PGJ2 was apoptotic. mOP cells were treated with
15d-PGJ2 for 24 h and assayed for apoptosis by staining
with the DNA-binding dye bisbenzimide, which can dem-
onstrate nuclear condensation characteristic of apoptosis,
and using the TUNEL staining method, which detects
apoptosis-associated DNA strand breaks [36]. In
untreated mOP cells, a small percentage (~3.8%) of the
cells displayed condensed nuclei when stained with bis-
benzimide (Fig. 2A). However, when mOP cells were
treated with 1 μM 15d-PGJ2 for 24 h the percentage of
cells with condensed nuclei doubled to 7.5% (Fig. 2A).
TUNEL staining revealed similar results where 2.5% of
untreated and 6.0% PGJ2-treated cells were positive for
TUNEL staining (Fig. 2B). Further evidence for 15d-PGJ2
induced apoptosis of mOP cells was obtained using an
ELISA-based cell death assay, which quantifies indirectly
the histone-containing nucleosomes generated due to
DNA fragmentation. In this assay, 15d-PGJ2 induced
apoptotic DNA fragmentation ~2-fold over that observed
in untreated cells (Fig. 2C). Lastly, we assessed DNA frag-
mentation (mono- and oligonucleosomes) in 15d-PGJ2-
treated mOP cells using agarose gel electrophoresis. 15d-
PGJ2 increased DNA fragmentation in mOP cells over thatJournal of Neuroinflammation 2007, 4:18 http://www.jneuroinflammation.com/content/4/1/18
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observed in untreated cells (Fig. 2D). Staurosporine
(STA), a well described inducer of apoptosis [37], induced
DNA fragmentation in mOP cells similar to that of 15d-
PGJ2-treated cells (Fig. 2C–D).
15d-PGJ2-induced apoptosis of mOP cells occurs 
independently of PPARγ or PGD2 receptors
15d-PGJ2 is a natural ligand for PPARγ and has been
shown to induce apoptosis in a variety of cell types
through a PPARγ-dependent pathway [6,8]. We therefore
investigated whether 15d-PGJ2-induced apoptosis in
mOP cells was through a PPARγ-dependent pathway. Real
time RT-PCR analysis demonstrated a small amount of
PPARγ amplification in mOP cells (data not shown). To
further examine whether PPARγ has a role in 15d-PGJ2
induced apoptosis of mOP cells we tested whether phar-
macological inhibition of PPARγ protects mOP cells from
the cytotoxic effects of 15d-PGJ2. Pre-incubation of mOP
cells with the irreversible PPARγ antagonists GW9662 (10
μM) or T0070907 (100 nM) did not block 15d-PGJ2-
induced apoptotic cell death (Fig. 3). These results pro-
Characterization of 15d-PGJ2-induced apoptosis in mOP  cells Figure 2
Characterization of 15d-PGJ2-induced apoptosis in 
mOP cells. mOP cells were treated with 15d-PGJ2 (1 μM) 
for 24 h, and then stained with the nuclear dye bisbenzimide 
or labeled with the TUNEL method. Cells with condensed 
nuclei (A) or that were TUNEL-positive (B) were counted, 
and expressed as percentage of the total number of cells. For 
apoptosis ELISA (C) and DNA fragmentation gel analysis (D), 
DNA from mOP cells that had been treated with 15d-PGJ2 
(5 μM) for 24 h was extracted and analyzed. Staurosporine 
(STA, 100 nM) treatment was used as positive control. M, 
molecular standards. Asterisks indicate significant difference 
versus control group (t-test, two-tailed, *(p < 0.05), **(p < 
0.01)).
The effect of PGs on the growth and survival of mouse oli- godendrocyte precursor (mOP) cells Figure 1
The effect of PGs on the growth and survival of 
mouse oligodendrocyte precursor (mOP) cells. (A) 
mOP cells express the oligodendrocyte precursor surface 
markers NG2 (red) and A2B5 (Green). Scale bar, 20 μm. (B) 
mOP cells were treated with PGE2 or PGF2α (0.1, 1 and 10 
μM) and examined using the MTT assay after 24 h. (C-D) 
mOP cells were treated with the indicated concentrations of 
PGD2 or 15d-PGJ2 and examined using the MTT assay after 
24 h. Data are the average of 3–4 experiments and expressed 
as percentage of the control group (vehicle treated). (E) 
mOP cells were treated with 15d-PGJ2 (1 μM) and examined 
using the LDH assay after 24 h and 48 h. Data are expressed 
as percentage of the total LDH. Asterisks indicate significant 
difference versus control group (One-way ANOVA with 
Dunnet posttest for C and D, Student t-test for E, *(p < 
0.05), **(p < 0.01).
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vide evidence that the cytotoxic effect of 15d-PGJ2 is not
mediated through the PPARγ pathway.
15d-PGJ2 has been reported to be an activator of the G-
protein-coupled receptor PGD2 DP2 [2]. To test whether
15d-PGJ2 exerts its effect through the PGD2 DP2 receptor,
mOP cells were pretreated with the non-specific DP antag-
onist AH6809 (which blocks both DP1 and DP2 recep-
tors) or the specific PGD2 DP2 receptor antagonist BAY-
u3405. Neither BAY-u3405 (5 μM) nor AH6809 (10 μM)
blocked 15d-PGJ2-induced death (Fig. 3). These results
suggest that 15d-PGJ2 induces mOP cell death independ-
ently of known membrane G-protein-coupled receptors
for PGD2.
15d-PGJ2 cytotoxicity and ROS
Previous reports have suggested that 15d-PGJ2 may
induce intracellular oxidative stress [38,39]. To examine
whether there is increased ROS production in 15d-PGJ2-
treated mOP cells we preloaded cells with the fluorescent
ROS probe DCFDA prior to 15d-PGJ2-treatment. ROS
production was significantly increased in mOP cells as
early as 45 min after treatment with 15d-PGJ2 (10 μM)
(Fig. 4A). Glutathione (GSH) is an important antioxidant
that protects cells from oxidative damage by ROS. We
therefore tested whether manipulations of the intracellu-
lar level of GSH could affect apoptotic cell death induced
by 15d-PGJ2. Pretreatment of mOP cells with NAC, which
is a precursor molecule for GSH synthesis and a reducing
agent for oxidized GSH [40], provided ~60% protection
against 15d-PGJ2 induced death, while pre-incubation
with the antioxidants ascorbic acid or α-tocopherol did
not provide protection (Fig. 4B). In contrast, application
of buthionine sulfoximine (BSO), an inhibitor for γ-
glutamylcysteinase synthatase [41] which depletes intrac-
ellular GSH (Fig. 4C), was toxic to mOP cells by itself and
sensitized mOP cells to a lower concentration of 15d-
PGJ2 (Fig. 4D). These results suggest that the toxicity of
15d-PGJ2 to mOP cells is related to intracellular GSH lev-
els.
15d-PGJ2 cytotoxicity involves free radical production and is  influenced by intracellular glutathione levels Figure 4
15d-PGJ2 cytotoxicity involves free radical produc-
tion and is influenced by intracellular glutathione lev-
els. (A) Time course of 15d-PGJ2-induced ROS production. 
mOP cells were preloaded with the fluorescent ROS probe 
DCFDA for 30 min, and then treated with 15d-PGJ2 (10 μM) 
for 1 h. ROS production was expressed as DCFDA fluores-
cence intensity (pixel value). (B) mOP cells were pre-treated 
or not with NAC (1 mM), Ascorbic acid (1 mM) or α-toco-
pherol (1 mM) for 1 h prior to treatment of 15d-PGJ2 (5 μM) 
for 24 h, toxicity was examined by counting the apoptotic 
cells with condensed nuclei. (C) mOP cells were treated or 
not with BSO (100 μM) for 4 h and the total level of intracel-
lular GSH was measured. (D) mOP cells were treated with 
BSO (100 μM) for 1 h and then co-treated with 15d-PGJ2 (1 
μM) for 24 h. Cells treated with BSO or 15d-PGJ2 alone or 
untreated were included as controls. Toxicity was examined 
by counting the apoptotic cells with condensed nuclei. Aster-
isks indicate significant difference (One-way ANOVA with 
Newman-Keuls or Dunnet posttest, or two way ANOVA 
with Bonferroni posttest, *(p < 0.05), **(p < 0.01) ***(p < 
0.001); two-tailed t-test used in C).
15d-PGJ2 cytotoxicity on mOP cells occurs independently of  PPARγ or PGD2 membrane receptors Figure 3
15d-PGJ2 cytotoxicity on mOP cells occurs inde-
pendently of PPARγ or PGD2 membrane receptors. 
mOP cells cultured on coverslips were treated with 15d-
PGJ2 (1 μM), in the absence or presence of the irreversible 
PPARγ antagonists GW9662 (GW, 10 μM) or T0070907 (T, 
100 nM), or nonspecific PGD2 receptor (DP) antagonist 
AH6809 (AH, 10 μM) or specific DP2 antagonist BAY-u3405 
(BAY, 5 μM) for 24 h, and apoptotic cell death was examined 
using bisbenzimide staining. Cells were counted and 
expressed as percentage of control (untreated). Data shown 
were average of three experiments. Asterisks indicate signifi-
cant difference versus control group (Two-way ANOVA 
Bonferroni posttest, **(p < 0.01), ***(p < 0.001)).Journal of Neuroinflammation 2007, 4:18 http://www.jneuroinflammation.com/content/4/1/18
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15d-PGJ2 cytotoxicity is dependent on the stage of 
oligodendrocyte maturation
Developmental stage susceptibility to various cytotoxic
stimuli has been reported previously [42-45]. We tested
whether the effect of 15d-PGJ2 on oligodendrocytes is
stage-dependent. mOP cells were induced to differentiate
in differentiation medium (DM). In contrast to the simple
morphology that undifferentiated mOP cells display
(97.7% with 3 or less processes and 2.3% with 4 to 6
branches, n = 287 cells) (Fig. 1A), differentiated mOP cells
display complex process formation (17.9% with 3 or less
processes, 50.2% with 4 to 6 branches, and 31.9% with
more than 6 branches, n = 304 cells). While displaying
increased immunoreactivity to the late stage markers π-
GST and MBP, differentiated mOP cells still showed punc-
tate staining to early stage OP cell marker A2B5 (Fig. 5A–
D).
When differentiated mOP cells were treated with 15d-
PGJ2, higher concentrations of 15d-PGJ2 were needed for
significant cytotoxicity as judged using MTT assay (Fig.
6A), with an EC50 of 9.8 μM. Maturation stage-specific
cytoxicity was also measured using apoptosis criteria
(condensed nuclei). While 1 μM 15d-PGJ2 was sufficient
to induce significant cell death of undifferentiated mOP
cells (see Fig. 2A), a 10-fold higher concentration of 15d-
PGJ2 was required to induce comparable death in differ-
entiated mOP cells (Fig. 6B). These results demonstrated
that differentiated mOP cells are more resistant to 15d-
PGJ2-induced cytotoxicity.
Discussion
While PGs have been shown to display a range of activities
on various cell types [1], few studies have been carried out
on cells within the oligodendrocyte lineage. Our data
indicate that PGD2/15d-PGJ2 may represent another
group of factors in addition to cytotoxic cytokines pro-
duced during inflammation that are toxic to OP cells.
PG production
Our results demonstrated that 15d-PGJ2 at ≥1 μM is toxic
to mouse OP cells. While baseline production of PGD2
from the whole mouse brain has been calculated to be
approximately 2 nM [46], higher concentrations may,
however, occur during inflammatory conditions. LPS
treatment can mimic inflammatory conditions and
induces PGD2/15d-PGJ2 production in mixed glial cell
cultures [24,25] and in animal models [26,27]. The pro-
duction of 15d-PGJ2 in the medium of primary microglial
cell cultures was calculated to be in the range of 10 nM
Micrographs showing mOP cell differentiation Figure 5
Micrographs showing mOP cell differentiation. mOP cells were induced to differentiate in DM. Differentiated mOP cells 
display elaborate process extension with secondary and tertiary branching (A, Phase), and immunostain positive for the mature 
oligodendrocyte markers πGST (B, Green) and MBP (D, Red). However, differentiated mOP cells still stain positive for the 
early stage OP cell marker A2B5, in a punctate fashion (C, Green). Scale bar, 20 μm.Journal of Neuroinflammation 2007, 4:18 http://www.jneuroinflammation.com/content/4/1/18
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[25]. However, it is likely that 15d-PGJ2 concentrations in
vivo can be orders higher because of the more confined
interstitial space. Indeed this has been observed previ-
ously for extracellular levels of glutamate. Upon inhibi-
tion of glutamate uptake the interstitial glutamate
concentration increases to over 100–150 times (200–300
nM) the minimal value maintainable by glutamate trans-
porters (2 nM) [47]. In a more recent study, 15d-PGJ2 was
found to be increased to 600 pg/mg protein [48] (~0.1
μM), in the ischemic cortex. These results suggest that the
toxic levels of 15d-PGJ2 we observed in our in vitro exper-
iments may also occur in vivo.
Death mechanism
Our results demonstrated that 15d-PGJ2 at 1 μM
decreases MTT values at 24 h by ~50%. This relatively
large reduction likely represents a combination of cell
death, reduced cell proliferation, and compromised mito-
chondrial activity. Using a more cell death specific LDH
assay, and an array of apoptotic assays, we demonstrated
that 15d-PGJ2 induces apoptotic cell death in mOP cells,
which has been observed in other cell types [6-11].
The mechanism(s) for this apoptosis has not been clearly
elucidated. While 15d-PGJ2 is a known ligand for PPARγ
and has been implicated in apoptosis in a variety of cell
types [6,8], in our studies 15d-PGJ2 induced apoptotic
death of mOP cells independently of PPARγ, since the
irreversible PPARγ antagonists GW9662 or T0070907 did
not provide protection. Consistent with our findings,
15d-PGJ2 toxicity is observed in hepatic myofibroblasts
that lack PPARγ expression [9].
15d-PGJ2 has been shown previously to induce free radi-
cal production [38,39], potentially due to its unsaturated
α, β carbonyl moieties in the cyclopentanone rings. In
addition, these moieties are capable of reacting with thiol
groups by Michael addition [49] and thus able to modify
the functions of important proteins such as thioredoxin
[39]. Reduced GSH is the most abundant non-protein
thiol group-containing molecule and can readily conju-
gate to 15d-PGJ2 via glutathione-S-transferase (GST).
Conjugation prevents free 15d-PGJ2 from attacking other
intracellular targets. In this regard, our studies show that
depleting intracellular GSH by BSO potentiates 15d-PGJ2-
induced cytotoxicity and increasing intracellular levels of
reduced GSH (by NAC) provides protection. In our study,
antioxidants such as ascorbic acid or α-tocopherol, which
act as electron donors to halt free radical production, pro-
vided no protection for the cytotoxic effect of 15d-PGJ2
on mOP cells. This has been observed previously in neu-
ronal cell types where ascorbic acid did not provide pro-
tection against PGJ2-induced toxicity [50], or dopamine-
induced apoptosis [51]. This lack of protection may be
due to ascorbic acid-mediated depletion of intracellular
GSH pool which would offset its beneficial effect [50].
Interestingly, in a study using cultured OP cells, ascorbic
acid provided no protection against cystine deprivation-
induced death, while α-tocopherol provided protection,
without blocking the depletion of intracellular GSH [42].
Taken together with our results these findings suggest that
ROS production may not be the only event responsible for
15d-PGJ2-induced cell death. These other events may
include reduction in mitochondrial membrane potential
[52], inhibition of NFκB activation [53], and inhibition of
transcription factor AP-1 associated [54] gene expression
that is involved in cell survival and apoptosis [1,55].
Of special interest, our studies demonstrate that 15d-PGJ2
is more toxic to early stage OP cells than to their more dif-
ferentiated counterpart. The higher resistance that mature
oligodendrocytes display has been reported previously in
response to lysophosphatidic acid [45], IFNγ [43],
cysteine deprivation and hydrogen peroxide (H2O2) treat-
ment [42,44]. Although the death mechanisms may be
different, they all include oxidative stress and suggest that
mature oligodendrocytes have a better system to fend off
oxidative stress. While GSH may be more directly
involved in providing protection against oxidative stress,
mature oligodendrocytes do not in fact have a higher GSH
level than immature oligodendrocytes [42]. In this regard,
maturational up-regulation of glutathione peroxidase
[44], π-glutathione-S-transferase [56] and L-PGDS (also a
GST) [57] in oligodendrocytes, may contribute to more
effective removal of electrophilic molecules such as 15d-
PGJ2.
Perspective
While our studies has demonstrated that 15d-PGJ2 is
cytotoxic to OP cells, we are aware that 15d-PGJ2 can have
effects on other cells that contribute to the demyelination
and remyelination process. Several previous cell culture
The effect of 15d-PGJ2-induced death is dependent on the  developmental stage of oligodendrocytes Figure 6
The effect of 15d-PGJ2-induced death is dependent 
on the developmental stage of oligodendrocytes. 
mOP cells were induced to differentiate in DM and then 
treated with 15d-PGJ2 for 24 h. Toxicity was examined by 
MTT assay (A) and by counting cells with condensed nuclei 
stained by the nuclear dye bisbenzimide (B). Asterisks indi-
cate significant difference (One-way ANOVA with Dunnet 
post test, *(p < 0.05), **(p < 0.01).Journal of Neuroinflammation 2007, 4:18 http://www.jneuroinflammation.com/content/4/1/18
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studies have shown that 15d-PGJ2 can inhibit activation
of microglia [25,58,59] and astrocytes [60], and is toxic to
microglia depending on its concentration [25]. Moreover,
systemic application of 15d-PGJ2 has been shown to be
protective in the rodent EAE model [61-63], which is con-
sistent with its inhibitory effect on microglia and immune
cells. However, the beneficial effect due to microglia inhi-
bition and toxic effect on OP cells are not mutually exclu-
sive. The pathological role of 15d-PGJ2 in vivo, therefore,
remains to be better defined and likely will depend on the
level of endogenous 15d-PGJ2 production. Further inves-
tigations, taking into consideration the interaction
between producer and recipient cells in a defined brain
area, are clearly warranted to elucidate the role of 15d-
PGJ2 in vivo.
Conclusion
In conclusion, we found that PGE2 and PGF2α have min-
imal effects on the growth and survival of mOP cells,
while PGD2 and 15d-PGJ2 induce apoptosis at low
micromolar concentrations independently of membrane
receptors for PGD2 and the nuclear receptor PPARγ. The
cytotoxicity of 15d-PGJ2 on mOP cells is associated with
the production of ROS, and affected by manipulations of
intracellular glutathione level but not by the free radical
scavengers ascorbic acid or α-tocopherol. Additionally,
15d-PGJ2 is more toxic to early stage OP cells than to dif-
ferentiated OP cells. Taken together, these results suggest
that 15d-PGJ2 may represent a deleterious factor in the
natural remyelination process in MS.
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